Michael Gubanski

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: RADIATION ONCOLOGY. 2024;19(1):27
Contouring practices and artefact management within a synthetic CT-based radiotherapy workflow for the central nervous system
Rossi E; Emin S; Gubanski M; Gagliardi G; Hedman M; Villegas F
Article: JOURNAL OF NEUROSURGERY. 2023;139(3):831-839
On the stability of Leksell Vantage stereotactic head frame fixation in Gamma Knife radiosurgery: a study based on cone-beam computed tomography imaging and the High Definition Motion Management system
Ghazal M; Fager M; Samadi A; Gubanski M; Benmakhlouf H
Article: BMJ OPEN. 2023;13(3):e070071
Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden
Heggebo LC; Borgen IMH; Rylander H; Kiserud C; Nordenmark TH; Hellebust TP; Evensen ME; Gustavsson M; Ramberg C; Sprauten M; Magelssen H; Blakstad H; Moorthy J; Andersson K; Raunert I; Henry T; Moe C; Granlund C; Goplen D; Brekke J; Johannessen T-CA; Solheim TS; Marienhagen K; Humberset O; Bergstrom P; Agrup M; Dahl L; Gubanski M; Gojon H; Brahme C-J; Ryden I; Jakola AS; Vik-Mo EO; Lie HC; Asphaug L; Hervani M; Kristensen I; Rueegg CS; Olsen IC; Ledal RJ; Degsell E; Werlenius K; Blomstrand M; Brandal P
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2021;110(4):993-1002
Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma
Giraud P; Racadot S; Vernerey D; Goldstein D; Glimelius B; Van Houtte P; Gubanski M; Spry N; Van Laethem JL; Hammel P; Huguet F
Article: PHYSICA MEDICA. 2019;60:120-126
An in silico planning study comparing doses and estimated risk of toxicity in 3D-CRT, IMRT and proton beam therapy of patients with thymic tumours
Lidestahl A; Mondlane G; Gubanski M; Lind PA; Siegbahn A
Article: RADIATION ONCOLOGY. 2018;13(1):206
Estimation of the risk for radiation-induced liver disease following photon- or proton-beam radiosurgery of liver metastases
Mondlane G; Ureba A; Gubanski M; Lind PA; Siegbahn A
Article: ANTICANCER RESEARCH. 2018;38(5):2619-2625
Estimation of Risk of Normal-tissue Toxicity Following Gastric Cancer Radiotherapy with Photon- or Scanned Proton-beams
Mondlane G; Ureba A; Gubanski M; Lind PA; Siegbahn A
Article: ACTA ONCOLOGICA. 2018;57(2):231-238
Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancer
Tsakonas G; Hellman F; Gubanski M; Friesland S; Tendler S; Lewensohn R; Ekman S; de Petris L
Article: PHYSICA MEDICA. 2017;42:263-270
Comparative study of the calculated risk of radiation-induced cancer after photon- and proton-beam based radiosurgery of liver metastases
Mondlane G; Gubanski M; Lind PA; Ureba A; Siegbahn A
Article: INTERNATIONAL JOURNAL OF PARTICLE THERAPY. 2016;3(2):277-284
Dosimetric Comparison of Plans for Photon- or Proton-Beam Based Radiosurgery of Liver Metastases.
Mondlane G; Gubanski M; Lind PA; Henry T; Ureba A; Siegbahn A
Article: MEDICAL ONCOLOGY. 2014;31(4):906
Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin)
Gubanski M; Glimelius B; Lind PA
Article: GASTRIC CANCER. 2010;13(3):155-161
Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
Gubanski M; Johnsson A; Fernebro E; Kadar L; Karlberg I; Flygare P; Berglund A; Glimelius B; Lind PA
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2010;77(4):1166-1170
INTEROBSERVER VARIATION OF CLINICAL TARGET VOLUME DELINEATION IN GASTRIC CANCER
Jansen EPM; Nijkamp J; Gubanski M; Lind PARM; Verheij M
Article: ACTA ONCOLOGICA. 2007;46(2):230-233
Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma
Lind PA; Naucler G; Holm A; Gubanski M; Svensson C

Alla övriga publikationer

Review: ACTA ONCOLOGICA. 2020;59(10):1157-1163
A Nordic-Baltic perspective on indications for proton therapy with strategies for identification of proper patients
Brandal P; Bergfeldt K; Aggerholm-Pedersen N; Backstrom G; Kerna I; Gubanski M; Bjornlinger K; Evensen ME; Kuddu M; Pettersson E; Brydoy M; Hellebust TP; Dale E; Valdman A; Weber L; Hoyer M
Published conference paper: ACTA ONCOLOGICA. 2017;56(6):832-838
Comparison of gastric-cancer radiotherapy performed with volumetric modulated arc therapy or single-field uniform-dose proton therapy
Mondlane G; Gubanski M; Lind PA; Ureba A; Siegbahn A
Review: ACTA ONCOLOGICA. 2007;46(3):277-285
Advances in the treatment of patients with gastric adenocarcinoma
Foukakis T; Lundell L; Gubanski M; Lind PA
Published conference paper: ACTA ONCOLOGICA. 2005;44(3):236-239
Capecitabine as third line therapy in patients with advanced colorectal cancer
Gubanski M; Naucler G; Almerud A; Lideståhl A; Lind PARM

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2024-2027
Anknuten till Undervisning/Handledning, Klinisk neurovetenskap, Karolinska Institutet, 2022-2025

Examina och utbildning

Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2015
Läkarexamen, Karolinska Institutet, 2000

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI